NDC 39822-0255-01 - CYCLOPHOSPHAMIDE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 39822-0255
- Requested NDC
- 39822-0255-01
- Package NDCs from labels
- 39822-0255-1, 39822-0255-01
- Manufacturer
- XGen Pharmaceuticals DJB, Inc.
- Effective date
- 2024-12-20
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CYCLOPHOSPHAMIDE - XGen Pharmaceuticals DJB, Inc. | XGen Pharmaceuticals DJB, Inc. | 2024-12-20 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 39822-0255-1 | CYCLOPHOSPHAMIDE | 50 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, LYOPHILIZED, | 50 | 4 | |
| 39822-0255-1 | CYCLOPHOSPHAMIDE | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 39822-0255 | CYCLOPHOSPHAMIDE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [XGEN PHARMACEUTICALS DJB, INC.] | 4 | Current NDC, 2 package rows | 20241222_02e64046-687d-449e-e063-6294a90a6c32.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 39822-0255-1 | EA - Each | 39822-0255 | da9293a1-2af2-4027-8bfc-63d46e2077b3 | 1 | 2024-03-12 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Nexus Pharmaceuticals, LLC | c961a1ac-6705-4756-9abc-9d84a6fcb5c8 | 2026-09-03 | Warnings, Adverse reactions | 8N3DW7272P |
| Frindovyx | CYCLOPHOSPHAMIDE | AVYXA Pharma, LLC | 5ad8ea65-4c98-487a-9c8d-df778765ec5e | 2026-08-26 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | OPKO Pharmaceuticals, LLC | d8057d1a-e8af-42ab-9da2-b545730b2655 | 2026-05-04 | Warnings, Adverse reactions | 8N3DW7272P |
| Mannitol | MANNITOL | Hospira, Inc. | 8ad3145e-00e7-4412-b9a5-06f00f264f30 | 2026-04-21 | Warnings, Adverse reactions | 3OWL53L36A |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | OPKO Pharmaceuticals, LLC | 7d6447e3-22c9-48d9-87c0-d0b576d7ea9e | 2026-04-21 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | BluePoint Laboratories | 1d3396d8-4c03-4a28-890a-d87c6c53a74e | 2026-03-12 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | BluePoint Laboratories | d7e97b99-83db-42d0-8521-b87fe6467a67 | 2026-02-12 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Avenacy, LLC | 1de02105-9c5b-4d11-bddf-bf8450d88b78 | 2026-02-01 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Amneal Pharmaceuticals LLC | 520bfe39-dfd5-4a20-9a37-80078afded0d | 2026-01-19 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | Bamboo US Bidco LCC | 2873b99a-830d-0a7b-e063-6394a90a4de7 | 2025-12-03 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Epic Pharma, LLC | 988d2f71-1dc7-45b5-b2df-187e68224973 | 2025-11-17 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| QR PAIN | ANALGESIC | MARYHELENE ENTERPRISES INC | 8f8f53e3-fe31-e7b5-e053-2995a90a710d | 2025-11-14 | Warnings | 3OWL53L36A |
| QR PAIN | ANALGESIC | MARYHELENE ENTERPRISES INC | 9984a510-30be-4013-e053-2995a90a841e | 2025-11-14 | Warnings | 3OWL53L36A |
| Mannitol | MANNITOL | ProPharma Distribution | 430669d7-9ad1-9a04-e063-6394a90ababb | 2025-11-07 | Warnings, Adverse reactions | 3OWL53L36A |
| Sorbitol-Mannitol | SORBITOL AND MANNITOL | ICU Medical Inc. | 5b44e248-4b7b-4777-954a-921c7b309944 | 2025-10-30 | Warnings, Adverse reactions | 3OWL53L36A |
| Mannitol | MANNITOL | ICU Medical Inc. | ba7bf864-8a4d-4262-8fd1-00174fa2f9d1 | 2025-10-24 | Warnings, Adverse reactions | 3OWL53L36A |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Civica, Inc. | 8627c83f-c057-495d-9f78-8b67bda97b3e | 2025-10-24 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Osmitrol | MANNITOL | Baxter Healthcare Company | 0d914965-7001-45cb-ba51-d7c5964b05bc | 2025-08-26 | Warnings, Adverse reactions | 3OWL53L36A |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Baxter Healthcare Company | 591d9955-3d9c-4cdc-a308-2f1288376b9f | 2025-06-24 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | Baxter Healthcare Company | 97ab446f-5017-4180-ae65-0a355289b0ed | 2025-06-20 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.